120 related articles for article (PubMed ID: 38159362)
1. Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial.
Wu MF; Cheng XY; Wang DY; Lai YT; Li H; Ye YF; Peng YP; Chen Q; Zhang BZ; Lin ZQ; Li J
Gynecol Oncol; 2024 Feb; 181():125-132. PubMed ID: 38159362
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose-finding trial of hyperthermic intraperitoneal docetaxel combined with cisplatin in patients with advanced-stage ovarian cancer.
You ZY; Wu MF; Li H; Ye YF; Wang LJ; Lin ZQ; Li J
J Gynecol Oncol; 2024 Jan; 35(1):e1. PubMed ID: 37477105
[TBL] [Abstract][Full Text] [Related]
3. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.
Gouy S; Ferron G; Glehen O; Bayar A; Marchal F; Pomel C; Quenet F; Bereder JM; Le Deley MC; Morice P
Gynecol Oncol; 2016 Aug; 142(2):237-42. PubMed ID: 27246305
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin, paclitaxel and escalating doses of doxorubicin (TAP) in advanced ovarian cancer: a phase I trial.
Onda T; Katsumata N; Tsunematsu R; Yasugi T; Mushika M; Yamamoto K; Fujii T; Hirakawa T; Kamura T; Saito T; Yoshikawa H
Jpn J Clin Oncol; 2004 Sep; 34(9):540-6. PubMed ID: 15466828
[TBL] [Abstract][Full Text] [Related]
5. A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy.
Chan CY; Li H; Wu MF; Liu CH; Lu HW; Lin ZQ; Li J
Front Oncol; 2021; 11():616264. PubMed ID: 33777754
[No Abstract] [Full Text] [Related]
6. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
Tew WP; Radovich D; O'Reilly E; Schwartz G; Schrag D; Saltz LB; Kelsen DP; Kepler S; Ilson DH
Invest New Drugs; 2009 Aug; 27(4):366-73. PubMed ID: 18956138
[TBL] [Abstract][Full Text] [Related]
7. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
[TBL] [Abstract][Full Text] [Related]
9. Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology.
Blum Murphy M; Ikoma N; Wang X; Estrella J; Roy-Chowdhuri S; Das P; Minsky BD; Song S; Mansfield P; Ajani J; Badgwell B
Ann Surg Oncol; 2020 Aug; 27(8):2806-2811. PubMed ID: 31974712
[TBL] [Abstract][Full Text] [Related]
10. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
[TBL] [Abstract][Full Text] [Related]
11. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study.
Nardi M; De Marco S; Fabi A; Aloe A; Magnani E; Pacetti U; Carlini P; Ruggeri EM; Cognetti F
Cancer Chemother Pharmacol; 2001 Sep; 48(3):255-8. PubMed ID: 11592349
[TBL] [Abstract][Full Text] [Related]
13. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
Cadoo KA; Grisham RN; O'Cearbhaill RE; Boucicaut NN; Henson M; Iasonos A; Zhou Q; Sarasohn DM; Gallagher J; Kravetz S; Zamarin D; Makker V; Sabbatini PJ; Tew WP; Aghajanian C; Konner JA
Gynecol Oncol; 2020 Apr; 157(1):214-221. PubMed ID: 31959492
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.
Polee MB; Verweij J; Siersema PD; Tilanus HW; Splinter TA; Stoter G; Van der Gaast A
Eur J Cancer; 2002 Jul; 38(11):1495-500. PubMed ID: 12110496
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.
Chambers SK; Chow HH; Janicek MF; Cragun JM; Hatch KD; Cui H; Laughren C; Clouser MC; Cohen JL; Wright HM; Abu Shahin N; Alberts DS
Clin Cancer Res; 2012 May; 18(9):2668-78. PubMed ID: 22421191
[TBL] [Abstract][Full Text] [Related]
20. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; DiSilvestro PA; Waggoner SE; Yamada SD; Armstrong DK; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Dec; 127(3):506-10. PubMed ID: 22943879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
